ALEXANDER LEMMER: Open Payments
NPI 1104168681 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,759 in 51 payments from 13 companies in 2025. Trend: 2023 $292 · 2024 $648 · 2025 $3,759
Speaker / faculty: $2,025Food & beverage: $1,734
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation | 15 | $2,338 |
| Madrigal Pharmaceuticals | 7 | $344 |
| Amgen Inc. | 10 | $321 |
| Gilead Sciences, Inc. | 8 | $206 |
| OrganOx LTD | 1 | $154 |
| AstraZeneca Pharmaceuticals LP | 1 | $117 |
| Novo Nordisk Inc | 1 | $89 |
| TriSalus Life Sciences, Inc. | 2 | $52 |
| Ethicon US, LLC | 1 | $43 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $40 |
Products named: General - Therapies, REZDIFFRA, EXALT Model D, UPLIZNA, METRA, TRINAV INFUSION SYSTEM, VISTASEAL, XIFAXAN.
Industry payments across GA — which companies pay providers there.
